Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
复制标题
DOI：
10.1007/s00198-009-1168-7
复制
发表时间：
2010-12-01
影响因子：
4
通讯作者：
Pavo, I.
中科院分区：
文献类型：
--
作者：
Stepan, J. J.;Burr, D. B.;Pavo, I.
特立帕肽治疗24个月后骨形成增加的水平（rhPTH (1-34)， TPTD）在治疗中（TN）或由于先前的阿仑膦酸钠（ALN）治疗而最初骨转换较低的患者中相似。TPTD对绝经后骨质疏松症妇女的骨合成代谢作用在从ALN转向TPTD的初始阶段可能会减弱。为了探讨长期影响，我们检测了长期ALN治疗后接受TPTD治疗的患者骨转换的组织形态学和生化指标。方法对29例aln预处理（64.5+/-16.4个月）和16例TN患者在基线和TPTD治疗24个月后进行四环素双标记后的配对活检。在基线、治疗期间或研究结束时测量生化指标。结果与基线相比，TPTD 24个月后，两组的激活频率（Ac.F）和骨样表面（OS）均增加：每年0.11-0.34个周期，aln预处理组为3.96-9.8%，每年0.19-0.33个周期，6.2-11.3% （p < 0.05）
The level of increased bone formation after 24 months of treatment with teriparatide (rhPTH (1-34), TPTD) is similar in patients who were either treatment-nave (TN) or had lower bone turnover initially due to previous alendronate (ALN) therapy.Introduction Bone anabolic effects of TPTD in postmenopausal women with osteoporosis may be blunted during the initial phase after switching from ALN to TPTD. To explore the long-term implications, we examined histomorphometric and biochemical markers of bone turnover of patients on TPTD therapy after long-term ALN treatment.Methods Paired biopsies were obtained after tetracycline double labeling at baseline and after 24 months of TPTD treatment from 29 ALN-pretreated (64.5+/-16.4 months) and 16 TN patients. Biochemical markers were measured at baseline, during the treatment, or at study end.Results Compared with the baseline, after 24-month TPTD, activation frequency (Ac.F.) and osteoid surface (OS) increased in both groups: 0.11-0.34 cycles per year, 3.96-9.8% in the ALN-pretreated group and 0.19-0.33 cycles per year, 6.2-11.3% (p